Danaher's revenue growth inflected from -0.9% in 2025Q1 to 8.3% in 2026Q3 as bioprocessing destocking eased, with operating margin recovering to 19.0% from 16.5% in 2024Q3, suggesting the Life Sciences portfolio is normalizing though durability of end-demand warrants monitoring.
Price trend, volume and key moving averages
Start with the evidence for owning the stock and the risks that can break the thesis.
Revenue growth accelerated to 8.3% in 2026Q3 with gross margin at 58.5% and operating margin at 19.0%, indicating incomplete but genuine operating leverage as SG&A discipline offsets a rising $433M R&D line.
Danaher is a leading global innovator in life sciences and diagnostics, committed to improving human health through science and technology.
The company has shown strong bioprocessing recovery, contributing to a 14.14% stock price appreciation since previous coverage.
Management's conservative 2026 guidance sets a baseline that could be exceeded, with projected high-single-digit EPS growth and 3-6% core revenue growth.
Trailing total returns as of 11/7/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC).
Check whether operating performance supports the current valuation.
Recent results and news deserve attention only when they alter the forward view.
| Quarter | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|
Q4 2026Latest Oct 21, 2026 | $2.11+9.9% vs $1.92 | $6.6B-0.1% vs $6.6B |
Q3 2026 Jul 21, 2026 | $1.94+4.9% vs $1.85 | $6.3B+2.4% vs $6.1B |
Q2 2026 Apr 21, 2026 | $2.06+6.2% vs $1.94 | $6.0B-0.5% vs $6.0B |
Q1 2026 Jan 28, 2026 | $2.23+3.2% vs $2.16 | $6.8B+0.4% vs $6.8B |
Associated Banc Corp acquired a new stake in shares of Danaher Corporation (NYSE: DHR) during the undefined quarter, according to its most recent Form 13F filing with the SEC. The institutional investor acquired 48,249 shares of the conglomerate's stock, valued at approximately $10,690,000. Other institutional investors and hedge funds have also bought and
International Assets Investment Management LLC boosted its position in shares of Danaher Corporation (NYSE: DHR) by 364.3% in the third quarter, according to the company in its most recent filing with the SEC. The firm owned 10,000 shares of the conglomerate's stock after acquiring an additional 7,846 shares during the quarter. International Assets
Bank Julius Baer and Co. Ltd Zurich trimmed its stake in Danaher Corporation (NYSE: DHR) by 67.5% during the third quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 101,849 shares of the conglomerate's stock after selling 211,896 shares during the period. Bank Julius Baer
WASHINGTON, Nov. 2, 2026 /PRNewswire/ -- Danaher Corporation (NYSE: DHR) announced that President and Chief Executive Officer, Julie Sawyer Montgomery, will be presenting at the UBS Global Healthcare Conference in Palm Beach, Florida on Monday, November 9, 2026 at 11:45 a.m. ET and Jefferies Global Healthcare Conference in London, UK on November 17, 2026 at 10:00 a.m.
Benchmark DHR against direct peers instead of judging its metrics in isolation.
Key metrics vs top competitors for Danaher Corporation (DHR)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $230.25 | $161.86B | 45.68 | 2.9% | 14.71% | 7.08% | 0.54% | |
| $694.76 | $258.19B | 39.16 | 3.91% | 14.96% | 13.3% | 0.24% | |
| $174.76 | $49.36B | 38.24 | 6.73% | 19.53% | 20.47% | 0.57% | |
| $457.60 | $34.22B | 42.53 | 6.99% | 1.75% | 0.81% | — | |
| $381.57 | $10.27B | 13.69 | 0.65% | 8.59% | 3.15% | — | |
| $61.31 | $9.33B | -408.73 | 2.08% | -2.03% | -2.87% | 0.24% |
Danaher Corporation (DHR) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
Verify the primary filings, follow material updates, and answer the remaining questions.
Danaher Corporation (DHR) SEC filings — annual & quarterly reports (10-K, 10-Q)
Oct 21, 2026·SEC
Oct 13, 2026·SEC
Aug 3, 2026·SEC
Get notified when DHR posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
Danaher Corporation (DHR) stock FAQ — growth, dividends, profitability & financials explained
Danaher Corporation (DHR) reported $25.61B in revenue over the trailing twelve months. Revenue was $24.57B in fiscal year 2025. That is 1256% more than the $1.81B of fiscal year 1996.
Danaher Corporation (DHR) grew revenue by 2.9% in fiscal year 2025, compared with the prior fiscal year.
Yes. Danaher Corporation (DHR) earned $4.33B in net income over the trailing twelve months (a 16.9% net margin).
Yes. Danaher Corporation (DHR) pays a dividend that yields 0.54% at the current price, a small yield.
Danaher Corporation (DHR) had a return on equity (ROE) of 7.1% in fiscal year 2025. That is below the market's typical 10-15%.
Danaher Corporation (DHR) generated $5.73B in free cash flow over the trailing twelve months.
